This bill amends RCW 72.09.780 (and related 2025 c 424 s 1912) to authorize and require the unnamed "department" to acquire, possess, sell, resell, deliver, dispense, distribute, and otherwise engage in activities that constitute the practice of pharmacy or wholesale distribution with respect to abortion medications. It directs the department to establish and operate a program to deliver, dispense, and distribute those medications to health care providers and health care entities for use in providing reproductive health care, including abortion care and medical management of early pregnancy loss. The department must comply with applicable law and licensing requirements but is expressly exempted from obtaining a wholesaler's license for actions taken pursuant to chapter 195, Laws of 2023 as provided in RCW 18.64.046. The department is permitted, but not required, to obtain payment for these activities and the section does not reduce any existing department authority. The bill defines "abortion medications" to include drugs used to induce termination of pregnancy or manage reproductive health care, and adopts various statutory definitions for terms such as deliver, dispense, distribute, person, practice of pharmacy, wholesale distribution, health care entity, and health care provider by reference to existing RCWs and WAC. It directs coordination with the Department of Health to identify and prioritize recipients, including Indian health care providers. An emergency clause makes the act effective immediately. The text repeatedly refers to "the department" but does not identify which state department; portions of the subsection labeling and a pricing/revenue paragraph appear bracketed or altered in the extracted text, so the final intended treatment of pricing, fees, and revenue deposit is unclear from these facts. No changes to criminal penalties are described in the provided material.

If enacted, an unnamed state department would be allowed to buy, hold, and distribute abortion medications such as mifepristone and misoprostol and to run a program that delivers those medicines in bulk to health care providers and health care entities (including Indian health providers and urban Indian organizations) for use in reproductive health care and management of early pregnancy loss. For providers this likely means more direct and potentially more reliable access to these medicines and the department may charge for them but is not required to do so. The department would pick up new operational duties—acquiring, storing, dispensing, coordinating with the Department of Health, and prioritizing recipients—and is expressly exempted from needing a wholesaler’s license for these actions under the cited law, which changes licensing requirements for the state program though it may affect existing suppliers. Key details are missing here: the bill text in these extracts does not say which department is responsible, how pricing or revenue will be handled, or how the program ties into the earlier statutes referenced, so expected costs, funding sources, and exact program rules are unclear.